A Phase 2 interventional study of OPC-34712 and Placebo in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 73 sites in 12 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-10-20.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 6th largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 2, and was the 2nd registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 459 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 21st largest by enrollment of the 111 interventional ones that give a count, is one of 3 that started in 2009, is one of 9 in phase 2, and was the 31st registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
This will be a multicenter, randomized, double-blind, placebo-controlled study designed to assess the tolerability, safety, and efficacy of OPC-34712 (0.25 to 6.0 mg) for the treatment of adult subjects hospitalized with an acute relapse of schizophrenia. Aripiprazole (10 to 20 mg) is included as a positive control to confirm the assay sensitivity of the study. A total of approximately 563 subjects will be screened at an estimated 75 sites worldwide in order to obtain approximately 450 randomized subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with a current Axis I diagnosis of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OPC-34712 0.25 mg arm
Drug: OPC-34712
OPC-34712 low-dose arm
Drug: OPC-34712
OPC-34712 mid-dose arm
Drug: OPC-34712
OPC-34712 high-dose arm
Drug: OPC-34712
Drug: Placebo
Aripiprazole arm
Drug: Aripiprazole
oral, once daily
Placebo
oral, once daily
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (Double Blind Phase)
The PANSS consists of three subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating absence of symptoms and a score of 7 indicating extremely severe symptoms. PANSS total score is the sum of the rating scores for 7 positive scale items, 7 negative scale items and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranges from 30-210, with higher scores indicating more severe symptoms.
Time frame: Baseline to Week 6
Change From Baseline to Week 6 in PANSS Positive Subscale Score (Double Blind Phase)
The PANSS consists of three subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating absence of symptoms and a score of 7 indicating extremely severe symptoms. The positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS positive subscale score is the sum of the rating scores for the 7 positive scale items from the PANSS panel. The PANSS positive subscale score ranges from 7-49, with higher scores indicating more severe symptoms.
Time frame: Baseline to Week 6
Change From Baseline to Week 6 in PANSS Negative Subscale Score (Double Blind Phase)
The PANSS consists of three subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating absence of symptoms and a score of 7 indicating extremely severe symptoms. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. PANSS negative subscale score is the sum of the rating scores for the 7 negative scale items from the PANSS panel. The PANSS negative subscale score ranges from 7-49, with higher scores indicating more severe symptoms.
Time frame: Baseline to Week 6
Change From Baseline to Week 6 in Personal and Social Performance Scale (PSP) (Double Blind Phase)
The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains. The rating is based on four main areas: (a) socially useful activities, including work and study; (b) personal and social relationships; (c) self-care; and (d) disturbing and aggressive behaviors. The ratings are converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Ratings from 71-100 reflect only mild difficulties. Ratings from 31-70 reflect manifest disabilities of various degrees. Ratings from 1-30 reflect functioning so poor that intensive support or supervision is needed.
Time frame: Baseline to Week 6
Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score (Double Blind Phase)
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices include the following: 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients
Time frame: Baseline to Week 6
Mean Clinical Global Impression - Improvement (CGI-I) at Week 6
The rater or investigator rated the particpant's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the participant's condition at baseline prior to the first dose of double-blind study medication. Response choices included the following: 0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
Time frame: Week 6
Response Rate at Week 6
Response rate was defined as a reduction of ≥ 30% from baseline in PANSS Total Score; or a CGI-I score of 1 (very much improved) or 2 (much improved) at Week 6
Time frame: Week 6
Discontinuation Rate for Lack of Efficacy or Receipt of Open Label OPC-34712
Efficacy-related discontinuation rate was assessed
Time frame: Baseline to Week 6
459 participants recruited at 74 study centres in the United States, Asia and Europe. Participants not responding adequately to treatment at Week 4 visit could continue in study and receive open-label OPC-34712 (starting dose 2.5 mg/day with option for decrease to 2 mg/day or increase to 3 mg/day) until Week 6 at study physician's discretion.
| Milestone | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High Dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Started | 42 | 89 | 90 | 93 | 50 | 95 |
| Completed | 20 | 52 | 53 | 56 | 34 | 53 |
| Not completed | 22 | 37 | 37 | 37 | 16 | 42 |
| Withdrew: Switched to open label rescue | 7 | 17 | 11 | 11 | 4 | 15 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 3 | 4 | 5 | 11 | 3 | 5 |
| Withdrew: Withdrawal by subject | 5 | 13 | 15 | 11 | 4 | 13 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 6 | 3 | 5 | 4 | 4 | 8 |
The PANSS consists of three subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating absence of symptoms and a score of 7 indicating extremely severe symptoms. PANSS total score is the sum of the rating scores for 7 positive scale items, 7 negative scale items and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranges from 30-210, with higher scores indicating more severe symptoms.
| Units on a scale | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (Double Blind Phase) | -9.76 ± 19.29 | -18.73 ± 20.27 | -16.19 ± 18.55 | -18.25 ± 20.49 | -17.98 ± 21.32 | -14.40 ± 20.13 |
The PANSS consists of three subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating absence of symptoms and a score of 7 indicating extremely severe symptoms. The positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS positive subscale score is the sum of the rating scores for the 7 positive scale items from the PANSS panel. The PANSS positive subscale score ranges from 7-49, with higher scores indicating more severe symptoms.
| Units on a scale | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Positive Subscale Score (Double Blind Phase) | -3.22 ± 5.26 | -5.97 ± 7.12 | -4.94 ± 6.17 | -5.98 ± 6.72 | -6.60 ± 7.16 | -4.82 ± 6.34 |
The PANSS consists of three subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating absence of symptoms and a score of 7 indicating extremely severe symptoms. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. PANSS negative subscale score is the sum of the rating scores for the 7 negative scale items from the PANSS panel. The PANSS negative subscale score ranges from 7-49, with higher scores indicating more severe symptoms.
| Units on a scale | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Negative Subscale Score (Double Blind Phase) | -1.93 ± 5.24 | -3.61 ± 5.15 | -3.84 ± 5.09 | -3.99 ± 5.40 | -3.00 ± 5.74 | -3.17 ± 4.88 |
The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains. The rating is based on four main areas: (a) socially useful activities, including work and study; (b) personal and social relationships; (c) self-care; and (d) disturbing and aggressive behaviors. The ratings are converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Ratings from 71-100 reflect only mild difficulties. Ratings from 31-70 reflect manifest disabilities of various degrees. Ratings from 1-30 reflect functioning so poor that intensive support or supervision is needed.
| Units on a scale | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in Personal and Social Performance Scale (PSP) (Double Blind Phase) | 4.54 ± 13.25 | 11.36 ± 14.84 | 10.67 ± 15.21 | 12.17 ± 14.72 | 10.66 ± 13.13 | 7.56 ± 14.90 |
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices include the following: 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients
| Units on a scale | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score (Double Blind Phase) | -0.39 ± 0.86 | -0.99 ± 1.29 | -0.87 ± 1.11 | -1.10 ± 1.24 | -1.00 ± 1.21 | -0.82 ± 1.16 |
The rater or investigator rated the particpant's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the participant's condition at baseline prior to the first dose of double-blind study medication. Response choices included the following: 0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
| Units on a scale | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Mean Clinical Global Impression - Improvement (CGI-I) at Week 6 | 3.66 ± 1.48 | 3.08 ± 1.58 | 3.17 ± 1.45 | 3.04 ± 1.50 | 3.04 ± 1.52 | 3.34 ± 1.54 |
Response rate was defined as a reduction of ≥ 30% from baseline in PANSS Total Score; or a CGI-I score of 1 (very much improved) or 2 (much improved) at Week 6
| Percentage of participants | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Response Rate at Week 6 | 40.5 | 57.3 | 46.7 | 51.6 | 60.0 | 49.5 |
Efficacy-related discontinuation rate was assessed
| Percentage of participants | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| Discontinuation Rate for Lack of Efficacy or Receipt of Open Label OPC-34712 | 31 | 22.5 | 17.8 | 16.1 | 16.0 | 24.2 |
Collected over Adverse events (AEs) were recorded from the time of signing the informed consent, during the 6-week treatment period and up to 30 days after the last dose of study medication. The AEs presented are for the double blind phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OPC-34712 0.25 mg | — | 0/42 (0%) | 20/42 (47.6%) |
| OPC-34712 Low-dose | — | 3/89 (3.4%) | 41/89 (46.1%) |
| OPC-34712 Mid-dose | — | 5/90 (5.6%) | 36/90 (40%) |
| OPC-34712 High-dose | — | 4/93 (4.3%) | 52/93 (55.9%) |
| Aripiprazole | — | 2/50 (4%) | 22/50 (44%) |
| Placebo | — | 3/95 (3.2%) | 39/95 (41.1%) |
| Event | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/42 | 1/89 | 1/90 | 0/93 | 1/50 | 0/95 |
| Complex partial seizuresNervous system disorders | 0/42 | 0/89 | 0/90 | 0/93 | 1/50 | 0/95 |
| Ankle fractureInjury, poisoning and procedural complications | 0/42 | 1/89 | 0/90 | 0/93 | 0/50 | 0/95 |
| SchizophreniaPsychiatric disorders | 0/42 | 1/89 | 1/90 | 1/93 | 0/50 | 1/95 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/42 | 0/89 | 1/90 | 0/93 | 0/50 | 0/95 |
| DizzinessNervous system disorders | 0/42 | 0/89 | 1/90 | 0/93 | 0/50 | 0/95 |
| Schizophrenia, paranoid typePsychiatric disorders | 0/42 | 0/89 | 1/90 | 1/93 | 0/50 | 0/95 |
| DeathGeneral disorders | 0/42 | 0/89 | 0/90 | 1/93 | 0/50 | 0/95 |
| Psychotic disorderPsychiatric disorders | 0/42 | 0/89 | 0/90 | 1/93 | 0/50 | 1/95 |
| AnxietyPsychiatric disorders | 0/42 | 0/89 | 0/90 | 0/93 | 0/50 | 1/95 |
| Event | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo |
|---|---|---|---|---|---|---|
| InsomniaPsychiatric disorders | 4/42 | 12/89 | 9/90 | 9/93 | 4/50 | 16/95 |
| AkathisiaNervous system disorders | 1/42 | 6/89 | 5/90 | 14/93 | 2/50 | 4/95 |
| HeadacheNervous system disorders | 6/42 | 8/89 | 13/90 | 7/93 | 3/50 | 10/95 |
| AnxietyPsychiatric disorders | 5/42 | 7/89 | 6/90 | 10/93 | 5/50 | 10/95 |
| Weight increasedInvestigations | 1/42 | 6/89 | 9/90 | 6/93 | 3/50 | 3/95 |
| AgitationPsychiatric disorders | 4/42 | 4/89 | 4/90 | 7/93 | 5/50 | 4/95 |
| DyspepsiaGastrointestinal disorders | 4/42 | 4/89 | 3/90 | 4/93 | 1/50 | 7/95 |
| ConstipationGastrointestinal disorders | 2/42 | 4/89 | 2/90 | 6/93 | 1/50 | 8/95 |
| DiarrhoeaGastrointestinal disorders | 3/42 | 5/89 | 1/90 | 4/93 | 4/50 | 3/95 |
| NauseaGastrointestinal disorders | 1/42 | 4/89 | 7/90 | 6/93 | 1/50 | 2/95 |
| Age, Continuous(Years) | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 40.4 ± 9.1 | 39.2 ± 10.3 | 37.4 ± 11.1 | 39.5 ± 11.1 | 40.8 ± 11 | 38.8 ± 11.4 | 39.1 ± 10.6 |
| Sex: Female, Male(Participants) | OPC-34712 0.25 mg | OPC-34712 Low-dose | OPC-34712 Mid-dose | OPC-34712 High-dose | Aripiprazole | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 15 | 36 | 30 | 38 | 16 | 37 | 172 |
| Male | 27 | 53 | 60 | 55 | 34 | 58 | 287 |
The record gives a start of Jul 2009, a primary completion of Sep 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 5 years after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →